PIK3CD and B-cell non-Hodgkin lymphoma: For example, in the setting of B cell lymphoma, delivery of a small-molecule Csk inhibitor could augment a tumor-specific T cell response while inhibiting the growth of transformed B cells by blocking their PI3K pathway.